Author

Katherine Sunderland

Observed name: K. Sunderland

Institution: BC Cancer Agency

Observed institutions: Tulane University, BC Cancer Agency, University of British Columbia, BC Cancer – Victoria

ORCID: 0000-0003-3194-7865

Observed ORCID: 0000-0003-3194-7865

OpenAlex ID: A5018535014

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 · Matti Annala, Gillian Vandekerkhove, et al. · Cancer Discovery · 517

PDF

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

2019 · Daniel J Khalaf, Matti Annala, et al. · The Lancet Oncology · 362

2018 · Daniel J. Khalaf, Katherine Sunderland, et al. · European Urology · 74

A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

2017 · Kim N. Chi, Matti Annala, et al. · Journal of Clinical Oncology · 36

Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.

2018 · Daniel Khalaf, Matti Annala, et al. · Journal of Clinical Oncology · 28

A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion

2017 · Sunil Parimi, Erica Tsang, et al. · Canadian Urological Association Journal · 22

PDF

Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study

2021 · Maryam Soleimani, Kevin Zou, et al. · European Journal of Cancer · 19

A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

2017 · Daniel Joseph Khalaf, Claudia M. Avilés, et al. · Canadian Urological Association Journal · 16

PDF

Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2016 · Sunil Parimi, Bernhard J. Eigl, et al. · Journal of Clinical Oncology · 14

A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer

2019 · Chan-Kyung Jane Cho, Katherine Sunderland, et al. · Practical Radiation Oncology · 11

Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).

2017 · Daniel Khalaf, Katherine Sunderland, et al. · Journal of Clinical Oncology · 10

PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).

2017 · Kim N. Chi, Mark T. Fleming, et al. · Journal of Clinical Oncology · 10

Long-Term Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy

2024 · Marie-Pier St-Laurent, George Acland, et al. · The Journal of Urology · 7

Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate

2022 · Jenny J. Ko, Julia Adams, et al. · Canadian Urological Association Journal · 7

PDF

Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer

2018 · Sunil Parimi, Suraya Bondy, et al. · Canadian Urological Association Journal · 6

PDF

Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy

2021 · Justin Oh, Bernhard Eigl, et al. · Canadian Urological Association Journal · 5

PDF

Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).

2022 · Daniel Joseph Khalaf, Liheng Chen, et al. · Journal of Clinical Oncology · 3

Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.

2018 · Steven Yip, Daniel Khalaf, et al. · Journal of Clinical Oncology · 3

Presenting Stage and Risk Group in Men Dying of Prostate Cancer

2020 · S. Parimi, S. Bondy, et al. · Current Oncology · 2

PDF

Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE)

2024 · Jenny J. Ko, Lawrence Mbuagbaw, et al. · Canadian Urological Association Journal · 1

PDF

Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.

2020 · Daniel J Khalaf, Katherine Sunderland, et al. · Journal of Clinical Oncology · 1

Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

2019 · Steven Yip, Katherine Sunderland, et al. · Journal of Clinical Oncology · 1

Reply by Author

2024 · Marie-Pier St-Laurent, George Acland, et al. · The Journal of Urology

Shifting Epidemiology of Carbapenemase-Producing Organisms: Time Series Analysis of the Provincial Surveillance Program in British Columbia, Canada from 2014-2023

2024 · Aidan McKerrell Nikiforuk, Shannon Russell, et al. · SSRN Electronic Journal

Clinical Predictors of Germline DNA Damage Repair Gene Mutations in Patients with Advanced Prostate Cancer

2023 · Steven Yip, Katherine Sunderland, et al. · Research Square

PDF

Works count: 34

Citation count: 1,155

H-index: 10

I10-index: 12